Spasmonet, tablets 40 mg 20 pcs

Spasmonet is an antispasmodic agent.

Pharmacodynamics

Drotaverine is a myotropic antispasmodic, similar in chemical structure and pharmacological properties to papaverine, but with a stronger and longer action.

Decreases influx of calcium ions into smooth muscle cells.

Limits smooth muscle tone of internal organs and intestinal peristalsis, dilates blood vessels. It does not affect the autonomic nervous system, does not penetrate into the CNS. Its direct effect on the smooth muscles allows it to be used as an antispasmodic when drugs from the group of M-cholinoblockers are contraindicated (closed-angle glaucoma, prostatic hypertrophy).

Pharmacokinetics

In oral administration absorption is high. Bioavailability is 100%.

Distributes evenly throughout tissues, penetrates smooth muscle cells.

Maximal concentration in blood reaches after 2 hours. Binding with plasma proteins is 80-90%.

The elimination half-life is 7-12 hours. Drotaverine is actively metabolized in the liver, excreted mainly by the kidneys, to a lesser extent with the bile. Does not penetrate the blood-brain barrier.

Indications

Gastroduodenitis, Colic, Pain, Meteorism, Gastric and duodenal ulcers, Colitis, Headache, Enteritis, cholecystitis, Gallic Colic, Gastritis, Bloating, Colic, Urolithiasis, GI spasms, Gallstone disease

Active ingredient

Drotaverine

Composition

1 tablet contains:

the active ingredient:

drotaverine hydrochloride 40.0 mg

excipients:

lactose monohydrate,

microcrystalline cellulose,

corn starch,

croscarmellose sodium,

colloidal anhydrous silica,

talk,

magnesium stearate.

How to take, the dosage

Overly, with a small amount of liquid.

Children under 6 years of age: in a single dose of 10-20 mg, the number of times a day is 1-2 times, the maximum daily dose is 120 mg.

Children aged 6 to 12 years: 1/2 tablet 2 times daily (20 to 40 mg drotaverine); maximum daily dose is 200 mg.

Adults and children over 12 years of age – 1-2 tablets 3 times a day (120 – 240 mg drotaverine).

Interaction

Drotaverine may weaken the antiparkinsonian effect of levodopa when used concomitantly.

It enhances the effect of papaverine, bendazole and other antispasmodics (including m-cholinoblockers), reduces blood pressure caused by tricyclic antidepressants, quinidine and procainamide. Phenobarbital increases the spasmolytic effect of drotaverine.

Drotaverine reduces the antispasmodic activity of morphine.

Special Instructions

Use Spasmonet with caution in severe coronary atherosclerosis.

Impact on the ability to drive and operate machinery.

When using the drug, it is necessary to refrain from driving and engaging in potentially dangerous activities requiring concentration and quick psychomotor reactions.

Contraindications

• Hypersensitivity,
• explicit renal and hepatic failure,
• chronic heart failure,
• corroding heart failure,
• trioventricular block of II and III degree,

cardiogenic shock,

arterial hypotension.

• trioventricular block of degree II and III,
• cardiogenic shock,
• arterial hypotension.

Pasmonet tablets contain lactose, so patients with congenital galactose intolerance, lactose deficiency or glucose-galactose malabsorption should not take the drug.

With caution: marked atherosclerosis of the coronary arteries, closed-angle glaucoma, prostatic hyperplasia.

Side effects

• Dizziness
• headache
• general weakness
• heart rhythm disturbance
• allergic reactions.

.

Overdose

In high doses it disrupts atrial-ventricular conduction, reduces excitability of the heart muscle, can cause cardiac arrest and paralysis of the respiratory center.

Pregnancy use

Administration of the drug during pregnancy and lactation is not contraindicated.

Prescribing caution when pregnant (1st trimester) and children under 6 years of age.

Similarities

No-shpa, Drotaverin, Drotaverin-Teva